Should minimal residual disease guide therapy in AML?

Medicine & Life Sciences

• Residual Neoplasm 100%
• Acute Myeloid Leukemia 89%
• Therapeutics 15%
• Skeleton 6%
• Drug Delivery Systems 5%
• Precursor Cell Lymphoblastic Leukemia-Lymphoma 5%
• High-Throughput Nucleotide Sequencing 5%
• Tumor Burden 5%
• Cell- and Tissue-Based Therapy 5%
• Leukemia 4%
• Bone Marrow 4%
• Genotype 4%
• Recurrence 3%

Chemical Compounds

• Drug 49%
• Reaction Yield 38%